Skip to main content

Lovastatin Pregnancy and Breastfeeding Warnings

Brand names: Altocor, Altoprev, Mevacor

Medically reviewed by Last updated on Sep 26, 2023.

Lovastatin Pregnancy Warnings

Use is contraindicated.

US FDA pregnancy category: X

Comments: Adequate methods of contraception should be encouraged.

While animal studies with simvastatin failed to reveal evidence of teratogenicity, animal studies with other HMG-CoA reductase inhibitors revealed an increase in the incidence of skeletal malformations. There are no controlled data in human pregnancy. However, HMG-CoA reductase inhibitors are known to inhibit biosynthetic processes necessary in fetal development.

Serum cholesterol and triglycerides increase during normal pregnancy, and are essential for fetal development. Because HMG-CoA reductase inhibitors decrease cholesterol synthesis, they cause fetal harm when administered to a pregnant woman. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia.

US FDA pregnancy category X: Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

See references

Lovastatin Breastfeeding Warnings

Use is contraindicated.

Excreted into human milk: Unknown
Excreted into animal milk: Yes

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. Product Information. Mevacor (lovastatin). Merck & Co., Inc. 2002.

References for breastfeeding information

  1. Product Information. Mevacor (lovastatin). Merck & Co., Inc. 2002.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.